Curated News
By: NewsRamp Editorial Staff
August 03, 2026

Oncotelic to Present at OTCQB Conference, Highlighting Everolimus Trial and AI Platforms

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Oncotelic's CEO presents at OTCQB conference, highlighting Phase 1b trial progress and platform validation, signaling potential investment edge.
  • Oncotelic advances Phase 1b Everolimus trial to next dose, expands European sites, and validates Deciparticle platform through peer-reviewed publications.
  • Oncotelic's AI and nanomedicine platforms aim to improve cancer treatment outcomes, making tomorrow better for patients worldwide.
  • Oncotelic's Deciparticle platform, validated by publications, uses AI and robotics for drug discovery, a fascinating blend of tech and medicine.

Impact - Why it Matters

This announcement matters because it signals Oncotelic's continued progress in advancing its oncology pipeline, particularly the Phase 1b Everolimus trial, which could lead to new treatment options for cancer patients. The company's focus on AI-driven drug discovery and nanomedicine platforms positions it at the forefront of innovative cancer therapies, potentially improving patient outcomes and offering investors a glimpse into the future of precision medicine.

Summary

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biotechnology company, is set to present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET, where CEO and Chairman Dr. Vuong Trieu will discuss the company's latest advancements and participate in a live Q&A session. Key progress to be highlighted includes the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, expansion of European clinical sites, validation of its Deciparticle platform through peer-reviewed publications, scalable cGMP manufacturing capabilities, and continued development of AI-driven drug discovery, robotics, and nanomedicine platforms.

Oncotelic is focused on developing innovative therapies for cancer and other serious diseases, leveraging precision medicine, RNA therapeutics, artificial intelligence, and advanced nanomedicine delivery technologies. The company's portfolio includes clinical-stage oncology assets, proprietary Deciparticle drug delivery technology, and AI-enabled drug discovery platforms. Investors can access the full press release at https://nnw.fm/fGHUt. The latest news and updates on OTLC are available in the company's newsroom at https://nnw.fm/OTLC.

NetworkNewsWire (NNW), a specialized communications platform, is the distributor of this news. NNW is part of the Dynamic Brand Portfolio @ IBN, which provides financial news and content distribution services. For more information, visit NetworkNewsWire.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic to Present at OTCQB Conference, Highlighting Everolimus Trial and AI Platforms

blockchain registration record for this content.